IL148019A0 - Composition comprising a tramadol material and an anticonvulsant drug - Google Patents

Composition comprising a tramadol material and an anticonvulsant drug

Info

Publication number
IL148019A0
IL148019A0 IL14801900A IL14801900A IL148019A0 IL 148019 A0 IL148019 A0 IL 148019A0 IL 14801900 A IL14801900 A IL 14801900A IL 14801900 A IL14801900 A IL 14801900A IL 148019 A0 IL148019 A0 IL 148019A0
Authority
IL
Israel
Prior art keywords
composition
anticonvulsant drug
tramadol material
tramadol
anticonvulsant
Prior art date
Application number
IL14801900A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL148019A0 publication Critical patent/IL148019A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL14801900A 1999-08-20 2000-08-09 Composition comprising a tramadol material and an anticonvulsant drug IL148019A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15020199P 1999-08-20 1999-08-20
PCT/US2000/021622 WO2001013904A2 (en) 1999-08-20 2000-08-09 Composition comprising a tramadol material and an anticonvulsant drug

Publications (1)

Publication Number Publication Date
IL148019A0 true IL148019A0 (en) 2002-09-12

Family

ID=22533492

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14801900A IL148019A0 (en) 1999-08-20 2000-08-09 Composition comprising a tramadol material and an anticonvulsant drug
IL148019A IL148019A (en) 1999-08-20 2002-02-05 Pharmaceutical preparations containing a combination of thermodol and a contraceptive drug and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148019A IL148019A (en) 1999-08-20 2002-02-05 Pharmaceutical preparations containing a combination of thermodol and a contraceptive drug and their use

Country Status (31)

Country Link
US (1) US6562865B1 (xx)
EP (1) EP1210118B1 (xx)
JP (1) JP4977297B2 (xx)
KR (1) KR100758609B1 (xx)
CN (1) CN1198651C (xx)
AR (1) AR032132A1 (xx)
AT (1) ATE284223T1 (xx)
AU (1) AU782759B2 (xx)
BG (1) BG65996B1 (xx)
BR (1) BRPI0013439B8 (xx)
CA (1) CA2381797C (xx)
CO (1) CO5190667A1 (xx)
CR (1) CR6593A (xx)
CZ (1) CZ2002524A3 (xx)
DE (1) DE60016602T2 (xx)
EA (1) EA006598B1 (xx)
ES (1) ES2234651T3 (xx)
HU (1) HUP0203198A3 (xx)
IL (2) IL148019A0 (xx)
MX (1) MXPA02001820A (xx)
MY (1) MY136985A (xx)
NO (1) NO332342B1 (xx)
NZ (1) NZ517106A (xx)
PL (1) PL213323B1 (xx)
PT (1) PT1210118E (xx)
SK (1) SK286621B6 (xx)
TR (1) TR200201067T2 (xx)
TW (1) TWI259769B (xx)
UA (1) UA75868C2 (xx)
WO (1) WO2001013904A2 (xx)
ZA (1) ZA200201403B (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG80535A1 (en) 1991-09-06 2001-05-22 Mcneilab Inc Composition comprising a tramadol material and acetaminophen and its use
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
MXPA02001820A (es) 1999-08-20 2003-07-14 Johnson & Johnson Composicion que comprende un material de tramadol y un farmaco anticonvulsivo.
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
US20030092759A1 (en) * 2001-09-24 2003-05-15 Abuzzahab Faruk S. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
IL163720A0 (en) * 2002-02-26 2005-12-18 Ortho Mcneil Pharm Inc Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
AU2003296672A1 (en) * 2002-12-13 2004-07-09 Cilag Ag Controlled release preparations comprising tramadol and topiramate
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
KR101043789B1 (ko) * 2003-03-31 2011-06-27 (주)에이스딕시오 디지털 신호 처리를 이용한 전력 측정기 및 그 전력 측정 방법과 그 방법을 수행하는 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체
CA2566468A1 (en) * 2004-05-19 2005-12-01 Laura Corradini Assay method
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0514278A (pt) * 2004-08-24 2008-06-10 Janssen Pharmaceutica Nv derivados de sulfamida de heteroarila benzo-fundida úteis como agentes anti-convulsivante
SG142306A1 (en) * 2004-10-15 2008-05-28 Janssen Pharmaceutica Nv Methods for neuroprotection
JP2008536928A (ja) * 2005-04-19 2008-09-11 アルザ・コーポレーシヨン トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
AU2007329779A1 (en) * 2006-10-27 2008-06-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating disruptive behavior disorders
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
US8356315B2 (en) * 2007-12-03 2013-01-15 Koncelik Jr Lawrence J Setting television default channel
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2340246A2 (en) 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
DK2331210T3 (da) * 2008-09-05 2014-08-11 Gruenenthal Gmbh Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika
WO2011023392A1 (en) 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
RU2533979C1 (ru) * 2013-03-11 2014-11-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ лечения центральных стенозирующих злокачественных опухолей трахеи и бронхов
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
DE102013009114A1 (de) * 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
KR20180093086A (ko) 2016-01-06 2018-08-20 론자 리미티드 개선된 생산을 위한 단백질 분해의 억제
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
WO2020044070A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
JP7257091B2 (ja) * 2019-06-27 2023-04-13 沼澤 敏彦 認知症の治療及び予防薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3562589A (en) * 1968-09-09 1971-02-09 Ite Imperial Corp Electrically resetting undervoltage trip for circuit breakers
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4587252A (en) * 1984-12-18 1986-05-06 Brighton Pharmaceutical, Inc. Hydrocodone/ibuprofen pharmaceutical compositions and method
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
PH31112A (en) 1991-09-06 1998-02-23 Mcneilab Inc Composition comprising a tramadol material and anyof codiene, oxycodone or hydrocodone and their use.
SG80535A1 (en) * 1991-09-06 2001-05-22 Mcneilab Inc Composition comprising a tramadol material and acetaminophen and its use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
PL191313B1 (pl) 1996-08-14 2006-04-28 Searle & Co Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania
JP2001500121A (ja) * 1996-08-23 2001-01-09 アルゴス ファーマシューティカル コーポレーション 神経障害性の痛みを治療する組成物を含む抗けいれん剤
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
IL134165A0 (en) * 1997-09-08 2001-04-30 Warner Lambert Co Analgesic compositions comprising anti-epileptic compounds and methods of using same
MXPA02001820A (es) 1999-08-20 2003-07-14 Johnson & Johnson Composicion que comprende un material de tramadol y un farmaco anticonvulsivo.

Also Published As

Publication number Publication date
ES2234651T3 (es) 2005-07-01
EA006598B1 (ru) 2006-02-24
CZ2002524A3 (cs) 2002-11-13
BG65996B1 (bg) 2010-09-30
CN1198651C (zh) 2005-04-27
JP4977297B2 (ja) 2012-07-18
ZA200201403B (en) 2003-07-30
NO332342B1 (no) 2012-09-03
ATE284223T1 (de) 2004-12-15
EA200200183A1 (ru) 2002-08-29
JP2003507421A (ja) 2003-02-25
NO20020728D0 (no) 2002-02-13
KR100758609B1 (ko) 2007-09-13
BRPI0013439A (pt) 2002-04-30
DE60016602D1 (de) 2005-01-13
AR032132A1 (es) 2003-10-29
NO20020728L (no) 2002-04-05
BRPI0013439B1 (pt) 2012-07-24
MXPA02001820A (es) 2003-07-14
IL148019A (en) 2012-03-29
PT1210118E (pt) 2005-02-28
CA2381797C (en) 2008-04-15
SK286621B6 (sk) 2009-02-05
BRPI0013439B8 (pt) 2021-07-06
EP1210118A2 (en) 2002-06-05
MY136985A (en) 2008-12-31
SK2262002A3 (en) 2003-02-04
AU6895800A (en) 2001-03-19
WO2001013904A3 (en) 2001-06-14
PL213323B1 (pl) 2013-02-28
HUP0203198A2 (hu) 2003-02-28
TR200201067T2 (tr) 2002-09-23
TWI259769B (en) 2006-08-11
AU782759B2 (en) 2005-08-25
WO2001013904A2 (en) 2001-03-01
DE60016602T2 (de) 2005-11-03
UA75868C2 (en) 2006-06-15
HUP0203198A3 (en) 2005-07-28
BG106420A (bg) 2002-09-30
US6562865B1 (en) 2003-05-13
PL353266A1 (en) 2003-11-03
CA2381797A1 (en) 2001-03-01
CN1379686A (zh) 2002-11-13
EP1210118B1 (en) 2004-12-08
NZ517106A (en) 2005-04-29
CO5190667A1 (es) 2002-08-29
KR20020025221A (ko) 2002-04-03
CR6593A (es) 2009-01-16

Similar Documents

Publication Publication Date Title
IL148019A0 (en) Composition comprising a tramadol material and an anticonvulsant drug
NZ513924A (en) Composition comprising a tramadol material and a selective cox-2 inhibitor drug
HK1066238A1 (en) Connecting material
EP1079034A4 (en) JOINING MATERIAL AND METHOD FOR MANUFACTURING SAID MATERIAL
AU2015499A (en) Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9921103D0 (en) Coated material
EP1043237A4 (en) PACKING BOX AND PACKAGING MATERIAL
HUP9701618A3 (en) Pharmaceutical composition containing tramadol and a calcium-canal-antagonist
GB9826315D0 (en) Forming compound and constructional material
HK1050476A1 (zh) 含有西布曲明和脂酶抑制劑的藥物組合物
GB2323832B (en) Material handling implement
DE60026493D1 (en) Blattförmiges photohärtbares material
GB9706815D0 (en) Material dispenser
GB9922562D0 (en) Implant material
GB9716057D0 (en) A material
GB9717320D0 (en) Polyconductive material
GB9901897D0 (en) Biological material and use thereof
GB9913198D0 (en) Isotopic reference material
GB9907469D0 (en) Labels and manufacture thereof
GB0103901D0 (en) Material delivery devices and methods
DK1210118T3 (da) Sammensætning omfattende et tramadolmateriale og et antikonvulsionslægemiddel
GB9927769D0 (en) Biological material and uses thereof
GB2346104B (en) Rigidised material
GB9902075D0 (en) Rigidised material
GB9706814D0 (en) Material dispenser